Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 (ADME)

An Open-label Study to Assess the Absorption, Distribution, Metabolism and Excretion, Including the Mass Balance, of [14C] Labeled BIA 5-1058 and Metabolites Following a Single Oral Dose Administration in Healthy Male Subjects

the purpose of this study is:

• to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7 Megabecquerel (MBq) of radiocarbon;
• to determine the pharmacokinetics (PK) of total radioactivity (TRA) in plasma and whole blood and to assess the blood-to-plasma ratio;
• to determine the PK of BIA 5-1058 and its metabolites in plasma.

Study Overview

• Status: Completed
• Conditions: Pulmonary Arterial Hypertension
• Intervention / Treatment: Drug: 400 mg BIA 5-1058

Detailed Description

This was a Phase 1, single-center, open-label, absorption, distribution, metabolism, and excretion study in 8 healthy adult male subjects. Subjects received a single oral dose of 400 mg BIA 5-1058, containing approximately 3.7 MBq (0.08 milliSievert [mSv]) of 14C-BIA 5-1058 as oral capsules. Screening was between Day -21 and Day -2 and confinement period was of one period in the clinic involving drug administration on Day 1, with admission on Day 1 and discharge on Day 15 (336 hours post-dose).

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands, 9728 NZ
    • PRA Health Sciences (PRA) - Early Development Services (EDS)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Gender :male
2. Age :18-65 years, inclusive
3. Body Mass Index (BMI) :18.0-30.0 kg/m2 (BMI [kg/m2] = Body weight [kg] ÷ Height2 [m2]) at screening
4. Subjects, if not surgically sterilized, were willing to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after discharge on Day 15. Adequate contraception for the male subject (and his female partner) was defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the volunteer, was acceptable
5. All prescribed medication had to be stopped at least 30 days prior to admission to the clinical research center
6. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's Wort) had to be stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol, which was allowed up to admission to the clinical research center
7. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate and "powerdrinks"), commercially available orange juice (because of a potential interaction of radioactivity and vitamin C), grapefruit (juice) and tobacco products from 48 hours prior to admission to in the clinical research center until discharge (Day 15)
8. Normal resting supine blood pressure and pulse showing no clinically relevant deviations as judged by the PI
9. Computerized (12-lead) ECG recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the PI
10. All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the PI
11. Willing and able to sign the ICF.

Exclusion Criteria:

1. Employee of PRA or the Sponsor
2. Evidence of clinically relevant pathology or a medical history of a major pathology as judged by the PI
3. Frequent headaches and/or migraine, recurrent nausea, and/or vomiting (more than twice a month)
4. Mental handicap (i.e. a general or specific intellectual disability, resulting directly or indirectly from injury to the brain or from abnormal neurological development)
5. History of relevant drug and/or food allergies
6. Smoking more than 5 cigarettes, 1 cigar or 1 pipe daily; the use of tobacco products in the 48 hours (2 days) prior to admission to the clinical research center on Day 1 was not allowed
7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
8. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)
9. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
10. Positive screen for hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibodies or anti human immunodeficiency virus (HIV) 1 and 2 antibodies
11. Participation in a drug study within 90 days prior to drug administration in the current study. Participation in more than 2 other drug studies in the 12 months prior to drug administration in the current study
12. Donation or loss of more than 100 mL of blood within 90 days prior to drug administration. Donation or loss of more than 1.5 liters of blood in the 10 months prior to drug administration in the current study
13. Subject with irregular bowel habits (more than 3 times a day or less than once every 2 days)
14. Strenuous exercise within 96 hours (4 days) prior to admission to the clinical research center
15. Significant and/or acute illness within 5 days prior to drug administration that may impact the safety of the subject, in the opinion of the PI
16. Participation in another ADME study with a radiation burden >0.1 mSv in the period of 1 year prior to screening
17. Exposure to radiation for diagnostic reasons (except dental X rays and plain X rays of thorax and bony skeleton [excluding spinal column]), during work or during participation in a clinical study in the period of 1 year prior to screening
18. Previous use of BIA 5 1058.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: BIA 5-1058; Capsules; 400 mg; single dose; oral administration.	Drug: 400 mg BIA 5-1058; Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).; Other Names: Zamicastat

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax - Maximum observed plasma concentration	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
Tmax - Time to attain maximum observed plasma concentration	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
AUC0-t Area under the plasma concentration-time curve up to time t, where t is the last point with concentrations above the lower limit of quantitation (LLOQ)	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
AUC0-inf - Area under the plasma concentration-time curve from time 0 extrapolated to infinity	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
t1/2 - Elimination half-life	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
CLR - Renal clearance	Pharmacokinetic Parameters for BIA 5-1058 (and Metabolites) in Plasma and for TRA in Plasma and Whole Blood. Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
Aeurine - Cumulative amount excreted in urine	Cumulative Recovery of Radioactivity in Urine URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15.).	Up to 20 days
Ae feces - Cumulative amount excreted in feces	Cumulative Recovery of Radioactivity in Feces FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. The pre dose sample was collected within 48 hours prior to drug administration (if collected at home before admission on Day 1, subjects recorded the time of collection and brought the sample at admission). From 48 h before returning to the clinic for the 24-hour collections, the subjects also collected stools at home and recorded the time of collection.	Up to 20 days
Aeair - Cumulative amount excreted in exhaled air	Cumulative Recovery of Radioactivity in Exhaled Air. EXHALED AIR sampling was at pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168 and 240 hours post dose (with possible extension at 336 hours post-dose, if needed).	Up to 20 days
Aetotal - Total amount excreted, calculated as Aeurine + Aefeces + Aeair	Cumulative Recovery of Radioactivity in Urine, Feces, Exhaled Air. URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15. FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. EXHALED AIR sampling was at pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168 and 240 hours post dose (with possible extension at 336 hours post-dose, if needed).	Up to 20 days
TRA t1/2 plasma	Excretion Rates of TRA in Plasma PLASMA Blood sampling was collected at pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168, 240 and 336 hours post-dose, and at 504 (±24 h), 672 (±24 h), 1008 (±48 h), 1344 (±48 h), and 1848 (±72 h) hours post-dose	Up to 20 days
TRA t1/2 urine	Excretion Rates of TRA in Urine URINE collection was at pre-dose (collected within 24 hours prior to drug administration) and at collection intervals of 0-6, 6-12, 12-24 and 24-48 hours post-dose, and in 24-hour collections intervals thereafter until discharge from the clinic on Day 15 (336 hours post-dose); and 24 hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day 15	Up to 20 days
TRA t1/2 feces	Excretion Rates of TRA in Feces FECES collection was at pre-dose and at collection intervals of 0-24, 24-48, 48 72, 72 96, 96 120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312 and 312-336 hours post-dose; and 24-hour collections on Days 21/22, 28/29, 42/43, 56/57 and 77/78, depending on recovery limits as assessed initially after Day. The pre dose sample was collected within 48 hours prior to drug administration (if collected at home before admission on Day 1, subjects recorded the time of collection and brought the sample at admission). From 48 h before returning to the clinic for the 24-hour collections, the subjects also collected stools at home and recorded the time of collection.	Up to 20 days

Collaborators and Investigators

• Sponsor: Bial - Portela C S.A.

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 31, 2017
• Primary Completion (ACTUAL): May 24, 2017
• Study Completion (ACTUAL): May 24, 2017

Study Registration Dates

• First Submitted: July 28, 2021
• First Submitted That Met QC Criteria: July 28, 2021
• First Posted (ACTUAL): August 5, 2021

Study Record Updates

• Last Update Posted (ACTUAL): August 5, 2021
• Last Update Submitted That Met QC Criteria: July 28, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension, Pulmonary; Hypertension; Pulmonary Arterial Hypertension; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Zamicastat
• Other Study ID Numbers: BIA-51058-104; 2015-002407-28 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No